Loading...
Loading...
Swedish
Orphan Biovitrum AB (publ) (Sobi)
SOBI and Hyperion Therapeutics
announced today that Sobi has been granted the exclusive rights
by Hyperion to distribute RAVICTI (glycerol phenylbutyrate) Oral Liquid on a
named patient basis for the chronic treatment of Urea Cycle Disorders (UCD) in
the Middle East. Under the agreement, Sobi receives the rights to provide
RAVICTI in Saudi Arabia, Oman, United Arab Emirates, Jordan, Kuwait, Qatar and
Bahrain. Financial details were not disclosed.
"We are proud of this partnership with Hyperion and RAVICTI is a perfect fit
with our existing UCD business and the capabilities within our Genetics
Therapeutic Area," said Geoffrey McDonough, President and CEO at Sobi. "We
believe the recent FDA approval of RAVICTI can allow us to provide access for
this important therapy in the Middle East."
UCD patients lack enzymes or transporters necessary for the conversion of
ammonia to urea and experience heightened levels of ammonia in the bloodstream.
Left untreated, UCDs can result in neurological damage, coma, and/or death.
Approved by the Food and Drug Administration on February 1, 2013, RAVICTI is an
oral medication used for the long-term management of high blood levels of
ammonia.
- - -
About RAVICTI
In short term clinical studies involving more
See full press releaseLoading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in